NAD+
experimentalAlso known as: Nicotinamide adenine dinucleotide
**Mechanism of Action** NAD+ (nicotinamide adenine dinucleotide) is a central redox cofactor mediating electron transfer in oxidative phosphorylation and glycolysis. It also serves as a substrate for sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38 enzymes, linking cellular energy status to epigenetic regulation, DNA repair, and calcium signaling. Age-related NAD+ decline impairs mitochondrial function and activates inflammatory pathways, driving interest in supplementation strategies (e.g., NMN, NR) to restore intracellular NAD+ pools. **Key Research Findings** Preclinical studies demonstrate that NAD+ precursors enhance mitochondrial biogenesis, improve insulin sensitivity, and extend healthspan in rodent models. PARP hyperactivation during genotoxic stress accelerates NAD+ depletion, while sirtuin activation via NAD+ repletion reduces age-associated inflammation and neurodegeneration. Human trials remain limited but show modest improvements in muscle function and metabolic markers; however, long-term efficacy and tissue-specific bioavailability are unresolved. **Clinical Relevance** NAD+ restoration is under investigation for metabolic disorders, neurodegenerative diseases, and sarcopenia. Despite promising preclinical data, clinical translation is constrained by inconsistent pharmacokinetics, potential tumor-promoting effects (via PARP inhibition), and lack of validated biomarkers. Current evidence supports experimental use only. For research purposes only — not medical advice.
Key data
C21H27N7O14P2Research & studies
NAD+ levels fall in response to stress and can be replenished through supplementation, but much about its biology remains poorly understood.; The microbiome modulates availability of NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).; Multiple cellular compartments have distinct pools of NAD+ and NADH, and non-canonical degradation pathways exist.; Ongoing controversies in the field underscore the need for more research on NAD+ detection and metabolism in specific cells and compartments.
NAD+ levels decline with aging and in age-related diseases.; NAD+ reduction affects all hallmarks of aging.; NAD+ precursors show potential in promoting healthy aging and improving neurodegeneration in preclinical studies.; Clinical trials with NAD+ precursors are underway for accelerated aging, Alzheimer's, and Parkinson's.
NAD metabolism interfaces with multiple aging hallmarks, including cellular senescence.; Low NAD+ can promote senescence via DNA damage and mitochondrial dysfunction.; Low NAD+ during aging may inhibit SASP development due to high metabolic demands.; Combining NAD replacement therapies with senolytic agents needs further study.
Niacin has homeostatic roles in NAD+ supplementation and metabolism.; Receptor-mediated activities include regulation of immune responses and phagocytosis of myelin debris or amyloid beta.; Niacin has been investigated in multiple sclerosis, Alzheimer's disease, Parkinson's disease, glioblastoma, and amyotrophic lateral sclerosis.; The prospect of niacin as a therapeutic for neurological impairment is promising.
NAD+ levels were reduced and inflammatory markers increased in APP/PS1 mouse brains.; NR treatment reduced proinflammatory cytokines, microglial activation, NLRP3 inflammasome expression, DNA damage, apoptosis, and cellular senescence.; cGAS-STING elevation in AD mice was normalized by NR treatment, with cell culture experiments suggesting a cGAS-STING-dependent pathway.; NR treatment induced mitophagy and improved cognitive and synaptic functions in AD mice.
NAD+ depletion is a causative factor in inherited and acquired human diseases.; Primary deficiencies result from impaired biosynthesis; secondary from increased consumption or dietary deficiency.; Pathological phenotypes range from congenital malformations to age-related diseases.; NAD+-enhancing agents show therapeutic potential for treating rare and common diseases.
Frequently asked questions
What is NAD+?
**Mechanism of Action** NAD+ (nicotinamide adenine dinucleotide) is a central redox cofactor mediating electron transfer in oxidative phosphorylation and glycolysis. It also serves as a substrate for sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38 enzymes, linking cellular energy status to epigenetic
How does NAD+ work?
Essential redox cofactor and sirtuin/PARP substrate whose restoration is studied for mitochondrial and metabolic aging.
What is the research status of NAD+?
NAD+ is currently classified as experimental, with 46,728 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of NAD+?
NAD+ has a molecular weight of approximately 663.4 g/mol (formula C21H27N7O14P2).
Related peptides
Mitochondrial-derived 24-aa peptide with cytoprotective, anti-apoptotic, and insulin-sensitizing effects in aging and neurodegeneration models.
Mitochondria-targeting tetrapeptide that binds cardiolipin on the inner membrane to stabilize cristae and restore ATP production.
Khavinson tetrapeptide reported to activate telomerase and normalize pineal melatonin rhythms in aging models.
D-retro-inverso peptide that disrupts FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells (senolytic).
Build on NAD+ data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key